Johnson & Johnson $JNJ Stock: Americana Partners LLC Increases Stake

Key Points

• Americana Partners increased its Johnson & Johnson stake by 15% in the third quarter, adding 33,017 shares to hold 252,933 shares worth approximately $67.0 million. Institutional investors own 69.55% of J&J’s stock.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $275.92, although recent insider sales and concerns about premium valuation and future earnings pressure present risks.
• J&J reported third-quarter adjusted earnings of $2.59 per share and $25.40 billion in revenue, both slightly above estimates, and declared a quarterly dividend of $1.34 per share, representing a 2.0% yield.

Americana Partners LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 15.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 252,933 shares of the company's stock after buying an additional 33,017 shares during the quarter. Johnson & Johnson accounts for about 1.4% of Americana Partners LLC's portfolio, making the stock its 19th largest position. Americana Partners LLC's holdings in Johnson & Johnson were worth $66,961,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. National Pension Service grew its holdings in Johnson & Johnson by 1.3% during the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company's stock valued at $1,327,493,000 after buying an additional 67,484 shares in the last quarter. IFP Advisors Inc grew its holdings in shares of Johnson & Johnson by 8.8% during the second quarter. IFP Advisors Inc now owns 38,760 shares of the company's stock worth $9,844,000 after purchasing an additional 3,133 shares during the last quarter. Elefante Mark B lifted its stake in shares of Johnson & Johnson by 9.8% during the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company's stock worth $7,285,000 after purchasing an additional 2,563 shares during the period. Gradient Investments LLC lifted its holdings in Johnson & Johnson by 9.9% in the second quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock worth $38,815,000 after acquiring an additional 13,737 shares during the last quarter. Finally, AMG Asset Management Group Inc. boosted its stake in shares of Johnson & Johnson by 172.0% during the 3rd quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company's stock valued at $1,020,000 after buying an additional 2,436 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on JNJ shares. Freedom Capital raised Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 16th. UBS Group set a $270.00 price target on Johnson & Johnson in a research report on Wednesday, October 14th. JPMorgan Chase & Co. lifted their target price on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 29th. Argus set a $300.00 target price on Johnson & Johnson in a research note on Wednesday, July 29th. Finally, Johnson Rice lowered Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $275.92.

Insider Activity

In other news, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy Schmid sold 33,597 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 64,515 shares of company stock valued at $17,271,766 in the last 90 days. Company insiders own 0.16% of the company's stock.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Icotyde, J&J’s oral plaque-psoriasis treatment, is reportedly gaining traction among U.S. dermatologists and being prescribed earlier in the treatment process. Strong adoption could support pharmaceutical growth and help offset declines in older products. Does Johnson & Johnson Have a New Edge in Plaque Psoriasis?
• Positive Sentiment: J&J presented 26 abstracts at TCT 2026 supporting the safety, efficacy and cost-effectiveness of its Impella heart pumps. The data may strengthen the long-term outlook for the MedTech portfolio despite recent weakness. Johnson & Johnson Presents Impella Data at TCT 2026
• Positive Sentiment: J&J continues to be highlighted as a dependable dividend stock, supported by more than five decades of annual payout increases. That income profile can provide downside support for long-term investors. Dividend Kings With 50-Plus Years of Payout Increases
• Neutral Sentiment: J&J’s recent performance has been strong, with shares reportedly up 42% over the past year, helped by progress toward resolving talc litigation and growth from newer medicines. Analysts are debating whether that advance has already priced in much of the improvement. Johnson & Johnson Is Up 42% in a Year
• Neutral Sentiment: Broker sentiment remains generally favorable, but the article questions how much weight investors should place on consensus recommendations as J&J trades near its 52-week high and at an elevated earnings multiple. Johnson & Johnson Broker Ratings
• Negative Sentiment: MedTech growth slowed in the third quarter because of international-market challenges and weakness at Abiomed. Investors may be concerned that a rebound in the fourth quarter will not fully offset the segment’s short-term disappointment. JNJ MedTech Segment Disappoints in Q3
• Negative Sentiment: Analysts see potential earnings pressure in 2027, while the market is already assigning a premium valuation after strong gains. That combination increases the risk of profit-taking if growth slows. Johnson & Johnson Strong Q3 Growth, but 2027 Could Test Earnings
• Negative Sentiment: Pomerantz announced an investigation into potential claims on behalf of J&J investors. Although such announcements do not establish wrongdoing, they add headline and litigation risk. Pomerantz Investor Investigation

Johnson & Johnson Stock Up 0.1%

Johnson & Johnson stock opened at $273.39 on Monday. The firm has a market cap of $658.13 billion, a P/E ratio of 41.42, a P/E/G ratio of 2.70 and a beta of 0.22. Johnson & Johnson has a twelve month low of $185.12 and a twelve month high of $282.02. The business has a fifty day moving average of $265.74 and a two-hundred day moving average of $246.94. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business's quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio is presently 81.21%.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.